Kapitalmarknadsdag in Stockholm with several leading life science companies in which CombiGene also participated (In swedish)
Onsdagen 29 augusti arrangerade Biostock en kapitalmarknadsdag i Stockholm med flera ledande life science-bolag där också CombiGene deltog med VD Jan Nilsson och FoU chefen Karin Agerman. CombiGene AB, Medicon Village, SE-223-81 Lund. Besöksadress:...read more
The long-term study, part of CombiGene's epilepsy project, is a decisive preclinical proof-of-concept-study, the results of which will have a great bearing on the continued development of CombiGene's candidate drug, CG01. Heading the study at Skåne...read more
On the 9th of November, ARM (Alliance for Regenerative Medicine) together with Catapult (a British organisation for cell- and gene therapy) organised an investor day in London to present interesting and innovative companies at research’s forefront. Among...read more
Find it easy
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.